GREATER CHINA Economics PMI A strong rebound for non-manufacturing PMI. Sector Macau Gaming Dec 24 GGR below expectations; expect 2025 GGR to recover to 82% of 2019’s level. INDONESIA Update Mitra Keluarga Karyasehat (MIKA IJ/BUY/Rp2,540/Target: Rp3,300) Expect a double-digit earnings growth in 2025 MALAYSIA Sector Heal...
GREATER CHINA Strategy Alpha Picks: December Conviction Calls Add Desay, Meituan, Mengniu, Tencent, and Trip.com to our BUY list. Take profit from CATL. Update CR Mixc Lifestyle (1209 HK/BUY/HK$29.20/Target: HK$32.15) Takeaways from reverse roadshow in Shenzhen. China Resources Land (1109 HK/BUY/HK$23.25/Target:HK$32.40) Takeaways from reverse roadshow in Shenzhen. Small/Mid Cap Highlights Regina Miracle (2199 HK/Not Rated/HK$2....
GREATER CHINA Results Hong Kong Exchanges and Clearing (388 HK/BUY/HK$314.80/Target: HK$364.00) 3Q24: Risk-and-reward is more balanced. Upgrade to BUY. Han’s Laser (002008 CH/HOLD/Rmb24.42/Target: Rmb22.70) 3Q24: Net profit misses, but visibility of recovery improving. Downgrade to HOLD. New Oriental Education & Technology Group (EDU US/BUY/US$62.15/Target: US$85.00) 1QFY25: In line; moderated growth outlook in 2QFY25 on low seasonality. Update Xtep International Holdings (...
While Japan’s automakers have upped their game in the EV space, they remain laggards on the global stage. With the EV markets now in trouble, analyst Julie Boote assesses whether or not the Japanese assemblers have been vindicated in their more cautious approach to electrification.
On 6 June 2023, Sareum announced the successful dosing of the first subjects in a Phase 1a (single ascending dose) clinical trial for its lead programme SDC-1801. The dosing has started at a specialist clinical unit in Melbourne, Australia. The Phase 1a trial is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an oral formulation of SDC-1801 in healthy subjects. This will be a randomised, placebo-controlled trial with single and multiple ascending oral d...
14 February 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objec...
2CRSI : Nouvelle offre commune avec CGG – Acheter (1), obj. 4.30€ Cours: 2.91€ au 31/01/23 ALCHIMIE : Des perspectives 2023 difficiles – Conserver (3), obj. 2.40€ Cours: 2.82€ au 31/01/23 BASSAC : Ralentissement confirmé mais maîtrisé – Acheter (1), obj. 75.0€ Cours: 50.8€ au 31/01/23 BONDUELLE : Le frais US toujours en recul – Acheter (1), obj. 23.0€ Cours: 12.3€ au 31/01/23 CGG : Signature d'un accord avec 2CRSI – Conserver (3), obj. 0.80€ Cours: 0.77€ au 31/01/23 ECOSLOPS : Solide public...
Peu après la publication du plan stratégique et des résultats S1, nos échanges avec Alain Wilmouth (CEO) et Philippe Steinmetz (CFO) ont permis de faire un update opérationnel, de détailler les nouveaux axes de croissance et d'aborder l'épineuse question du bilan.
TRIGANO : Position cash perturbée, confiance pour 2022/23 - Contact – Acheter (1), obj. 158.0€ Cours: 111.8€ au 29/11/22 2CRSI : S1 plus difficile mais objectifs annuels confirmés / Contact – Acheter (1), obj. 4.30€ Cours: 2.44€ au 29/11/22 HERIGE : Finalise PORALU - Contact – Acheter (1), obj. 54.0€ Cours: 32.3€ au 29/11/22 LACROIX : Rend l'éclairage public d'Oslo intelligent – Acheter (1), obj. 47.6€ Cours: 27.1€ au 29/11/22 SII : S1 encore un peu mieux que prévu, avec toujours l'internati...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.